Hypersensitivity to social threat, anger, and (auto)aggression in BPD

Hypersensitivity to social threat, anger, and (auto)aggression in BPD - Anger_BPD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00003282

Enrollment

240

Registered

2011-10-18

Start date

2012-05-14

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F60.31 F43.1

Interventions

Group 1: All patients(N=50 female BPD patients, age: 15-40 years and N=35 male BPD patients, age: 18-40 years) participate at 3 occasions consisting of an extensive clinical diagnostic (occasion 1, du

Eligibility

Sex/Gender

All

Age

15 Years to 40 Years

Inclusion criteria

Inclusion criteria: General inclusion criteria: age of 15-40 years, readiness for participation. Additional inclusion criterium for boderline patients: Boderline personality disorder (DSM-IV). Additional inclusion criterium for PTBS-controls: posttraumatic stress disorder (DSM-IV)

Exclusion criteria

Exclusion criteria: General exclusion criteria: pregnancy, lifetime-diagnosis of schizophrenic disorder, bipolar-I-disorder, substance abuse within the last year. organic head injury, severe non-surgical or neurological brain disorder, craniocerebral injury, metallic residue, claustrophobia. Additional exclusion criteria for PTBS-controls: more than 1 DSM-IV criterium for BPD. Additional exclusion criteria for healthy controls: more than one DSM-IV criterium for BPD, any psychiatric disorder.

Design outcomes

Primary

Measure	Time frame
Experiment 1 (Behavioral study): Bias for anger in complex bimodal stimuli, comparison of BPD patients and healthy controls, and PTSD patients, measure: behavioral data. Experiment 2 (fMRI 1): A. Approach and avoidance tendencies for happy and angry faces, comparison of BPD patients and healthy controls, and PTSD patients, measure: reaction time data; B. activiations in the limbic system and prefrontal-amygdalar connectivity, comparison of BPD patients and healthy controls, and PTSD patients, measure: fMRI data; C. correlations between aggressiveness and gender with approach tendencies for angry faces, comparison of male and female BPD patients and male and female healthy controls, measures: reaction time data, aggressiveness questionnaire scores, fMRI data. Experiment 3 (fMRI 2): A. Strength of feelings of anger during imagination of aggressive and autoaggressive scripts, comparison of BPD patients and healthy controls, and PTSD patients, measures: subjective arousal ratings, fMRI, autonomic measures; B. activiations in the limbic system and prefrontal-amygdalar connetivity during anger induction, comparison of BPD patients and healthy controls, and PTSD patients, measure: fMRI.	—

Measure

Time frame

Experiment 1 (Behavioral study): Bias for anger in complex bimodal stimuli, comparison of BPD patients and healthy controls, and PTSD patients, measure: behavioral data. Experiment 2 (fMRI 1): A. Approach and avoidance tendencies for happy and angry faces, comparison of BPD patients and healthy controls, and PTSD patients, measure: reaction time data; B. activiations in the limbic system and prefrontal-amygdalar connectivity, comparison of BPD patients and healthy controls, and PTSD patients, measure: fMRI data; C. correlations between aggressiveness and gender with approach tendencies for angry faces, comparison of male and female BPD patients and male and female healthy controls, measures: reaction time data, aggressiveness questionnaire scores, fMRI data. Experiment 3 (fMRI 2): A. Strength of feelings of anger during imagination of aggressive and autoaggressive scripts, comparison of BPD patients and healthy controls, and PTSD patients, measures: subjective arousal ratings, fMRI, autonomic measures; B. activiations in the limbic system and prefrontal-amygdalar connetivity during anger induction, comparison of BPD patients and healthy controls, and PTSD patients, measure: fMRI.

—

Secondary

Measure	Time frame
Not given	—

Countries

Germany

Contacts

Public ContactKatja Bertsch

Klinik für Allgemeine Psychiatrie Universitätsklinikum Heidelberg

katja.bertsch@med.uni-heidelberg.de06221-5636502

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026